Objective: To analyze the impact of gefitinib and icotinib on medical insurance budget. Methods: The consumption of gefitinib, icotinib, erlotinib, molecular targeted anti-tumor drugs, antitumor drugs and all drugs in 2010-2015 was from Jiangsu medicine information institute. The insurance expenditure of antitumor drugs and all drugs was calculated by average reimbursement rate. The consumption and insurance expenditure in 2018 was predicted according to that in 2010-2015. The expenditure growth and its impact on anti-tumor drugs and all drugs were calculated under 90%, 80% and 70% reimbursement rate as the different incremental proportion of gefitinib and icotinib. Results: The predicted medical insurance expenditure of anti-tumor drugs and all drugs will be 1.327 and 12.40 billion in 2018. According to 90% reimbursement rate, the insurance expenditure of gefitinib and icotinib will increase to 13.53-34.44 million yuan, while anti-cancer drugs and all medical insurance drugs expenditure increased by 1.02%-2.60% and 0.11%-0.28% respectively while the consumption of gefitinib and icotinib increased 0-100% in 2018. The increment of medical insurance expenditure reduced accordingly under the reimbursement ratio of 80% and 70%. The increment of medical insurance expenditure reduced accordingly when only icotinib are covered by medical insurance. Conclusion: The budget impact of gefitinib and icotinib was not great on medical insurance expenditure of anti-cancer drugs，which was very limited on the medical insurance expenditure of all drugs.